References
- Tobelem G. Essential thrombocythaemia. Baillieres Clin Haematol 1989; 2: 719–728
- Slee P HT, Van Everdingen J JE, Geraedts J PM, Te Velde J, Den Ottolander G J. Familial myeloproliferative disease. Hematological and cytogenetic studies. Acta Med Scand 1981; 210: 321–327
- Eyster M E, Saletan S L, Rabellio E M. Familial essential thrombocythemia. Am J Med 1986; 80: 497–502
- Adams J A, Barrett A J, Beard J, McCarthy D M. Primary polycythaemia, essential thrombocythaemia and myelofibrosis–three facets of a single disease process. Acta Haematol 1988; 79: 33–37
- Sceats D J, Baitlon D. Primary thrombocythemia in a child. Clin Pediatr 1980; 19: 298–300
- La Huerta-Palacios J J, Bornstein R, Fernandez-Debora F J. Controlled and uncontrolled thrombocytosis. Its clinical role in essential thrombocythemia. Cancer 1988; 61: 1207–1212
- Amato D, Freedman M H. Eleven-year follow-up of “primary thrombocythemia” in a child. J Pediatr 1984; 104: 639
- Ozsoylu S. Thrombocythemia and myelofibrosis. J Pediatr 1985; 106: 693
- Fickers M, Speck B. Thrombocythaemia. Familial occurrence and transition into blastic crisis. Acta Haemat 1974; 51: 257–265
- Silverstein M N, Petitt R M, Solberg L A, Fleming J S, Knight R C, Schacter L P. Anagrelide: a new drug for treating thrombocytosis. N Engl J Med 1988; 318: 1292–1294